hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06339645, orgStudyIdInfo id: P00003121, briefTitle: Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder-A Retrospective Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-05-22, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Hualien Tzu Chi General Hospital, class: OTHER, descriptionModule briefSummary: The correlation of safety and effectiveness between intravesical platelet-rich plasma injection in patients with interstitial cystitis/bladder-A retrospective study to evaluate the correlation of safety and effectiveness between intravesical platelet-rich plasma injection of IC/BPS, with age of at least 20-84 years old in Taiwan of either sex with IC/BPS symptoms and proven of IC by cystoscopic hydrodistention. Patients who meet all eligibility requirements for entry into the study of intravesical PRP injection., conditionsModule conditions: Safety and Effectiveness Between Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 658, type: ESTIMATED, armsInterventionsModule interventions name: PRP, outcomesModule primaryOutcomes measure: Global response assessment (GRA), eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wan Ru Yu, city: Hualien City, state: Outside U.S./Taiwan, zip: 970, country: Taiwan, contacts name: Wan Ru Yu, role: CONTACT, phone: 0925051013, email: wanzu666@gmail.com, geoPoint lat: 23.97694, lon: 121.60444, hasResults: False
protocolSection identificationModule nctId: NCT06339632, orgStudyIdInfo id: AVAP-NG 3363, briefTitle: Effects of Transcutaneous Electrical Phrenic Nerve Stimulation and Transcutaneous Electrical Diaphragmatic Stimulation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Hospital Sirio-Libanes, class: OTHER, collaborators name: Hospital Israelita Albert Einstein, descriptionModule briefSummary: Transcutaneous electrical phrenic nerve stimulation (TEPNS) and transcutaneous electrical diaphragm stimulation (TEDS) are modalities that use surface electrodes placed on the patients' skin to generate action potentials and contractions of the muscle fibers of the diaphragm. The primary objective will be to evaluate the efficacy of TEPNS and TEDS in healthy adult individuals. Secondary objectives will be to assess the feasibility, safety, and level of discomfort reported by the individual resulting from the application of TEPNS and TEDS., conditionsModule conditions: Diaphragm, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: The researchers responsible for assessing diaphragm muscle through ultrasound will perform image recordings and captures during the "TEPNS" and "TEDS" intervention moments. Subsequently, the images will be analyzed by a blinded evaluator for the adopted intervention. The analyses will follow the methods described in the "diaphragm muscle mobility" and "diaphragm muscle thickness and thickening fraction" sections. Study participants will also be instructed not to disclose information regarding their experience and sensations during the intervention period, ensuring study blinding., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Transcutaneous electrical phrenic nerve stimulation (TEPNS), interventions name: Transcutaneous electrical diaphragm stimulation (TEDS), outcomesModule primaryOutcomes measure: Diaphragm mobility, primaryOutcomes measure: Diaphragm thickness, primaryOutcomes measure: Thickening fraction, secondaryOutcomes measure: Evaluation of sensory discomfort, secondaryOutcomes measure: Safety of TEPNS and TEDS application, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hospital Sírio Libanês, status: RECRUITING, city: São Paulo, zip: 01308-050, country: Brazil, contacts name: Renato F RIGHETTI, PhD, role: CONTACT, phone: 5511987496664, email: refragar@gmail.com, contacts name: Renato F Righetti, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Wellington P Yamaguti, PhD, role: SUB_INVESTIGATOR, contacts name: Ricardo K Nawa, PhD, role: SUB_INVESTIGATOR, geoPoint lat: -23.5475, lon: -46.63611, hasResults: False
protocolSection identificationModule nctId: NCT06339619, orgStudyIdInfo id: SYSKY-2023-1262-02, briefTitle: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2026-09-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, descriptionModule briefSummary: The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitors in combination with chemotherapy., conditionsModule conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab, interventions name: Apatinib, interventions name: Tegafur, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: ≥Grade 3 AEs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510030, country: China, contacts name: Minghui Wang, Dr., role: CONTACT, phone: 13826276828, email: wmingh@mail.sysu.edu.cn, contacts name: Minghui Wang, Dr., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06339606, orgStudyIdInfo id: 4316, briefTitle: Pregnancy Repository, acronym: PR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2031-04-30, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Sunnybrook Health Sciences Centre, class: OTHER, descriptionModule briefSummary: An essential part of clinical research is the availability and accessibility of human biospecimens for the identification of biomarkers, new treatments and measurement of response to therapy. Proteins, RNA and DNA can be extracted and studied as well. This is a critical first step in performing many fundamental molecular biology experiments. A variety of biospecimens are utilized for research including but not limited to normal and malignant tissues, blood, and other body fluids.In order to obtain high-quality biospecimens, they must be acquired serially, stored according to current standards, and matched with clinical information for maximum value. As such, the investigators would like to create a repository of biospecimens collected from pregnant patients who are seen at Mount Sinai Hospital and other research hospitals in Toronto. Mount Sinai provides personnel and infrastructure to serve the largest (7500 births/year) and highest complex Maternity program in Ontario. Of the 7500 patients a year, at least 2500 are considered high risk pregnancies, where there's a possibility of preeclampsia, placenta accreta and a host of other complications. For this study, biological specimens - blood, cervical and placental samples - will be collected from these high-risk groups in order to better understand the causes of the underlying conditions., conditionsModule conditions: Pregnancy Related, conditions: Fetal Growth Retardation, conditions: Placental Insufficiency, conditions: Preeclampsia, conditions: Cervix; Pregnancy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 7000, type: ESTIMATED, armsInterventionsModule interventions name: Biospecimen collection, outcomesModule primaryOutcomes measure: Biomarker levels, primaryOutcomes measure: Pathology, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06339593, orgStudyIdInfo id: 2023-0391, briefTitle: Regional Monitoring of CF Lung Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-05, primaryCompletionDateStruct date: 2028-01, completionDateStruct date: 2028-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Children's Hospital Medical Center, Cincinnati, class: OTHER, descriptionModule briefSummary: The main reason for this research study is to learn more about some new tests that are being developing for patients with Cystic Fibrosis (CF) to measure changes in the lungs. In this study, the focus will be to learn how stopping Airway Clearance (ACT) and re-starting ACT can affect these tests. These new tests include using a breathable gas called Xenon (Xe) with MRI (magnetic resonance imaging) to improve the pictures of changes in the lungs. The Xenon (Xe) gas that has been treated to have a larger MRI signal (also called hyperpolarized). The other new test is called LCI (Lung Clearance Index) that can measure how well the lungs are working. The MRI machine used in this study has been approved by the U.S. Food and Drug Administration (FDA) and is commercially available for sale in the USA. Hyperpolarized Xe gas is an FDA-approved, inhaled contrast agent for lung ventilation MRI. The new Xe MRI techniques that are being developed and used for this research study are investigational, meaning these new Xe MRI techniques are not FDA approved, but they are similar to FDA-approved techniques that are used clinically at Cincinnati Children's Hospital Medical Center (CCHMC). Xe gas and the new MRI techniques used in this research study have been used for many years in research, including in many research studies conducted at CCHMC like this one., conditionsModule conditions: Cystic Fibrosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Hyperpolarized Xe129, outcomesModule primaryOutcomes measure: Assessing structural and functional lung abnormalities via Xenon MRI, secondaryOutcomes measure: Assessing patients who have self-withdrawn airway clearance treatment to determine ventilation abnormalities., otherOutcomes measure: Change in Xenon Ventilation Defect Process (VDP), eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 21 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Cincinnati Children's Hospital, status: RECRUITING, city: Cincinnati, state: Ohio, zip: 45229, country: United States, contacts name: Carrie Stevens, BS, role: CONTACT, phone: 513-636-9973, email: carrie.stevens@cchmc.org, geoPoint lat: 39.12713, lon: -84.51435, hasResults: False
protocolSection identificationModule nctId: NCT06339580, orgStudyIdInfo id: 324456, briefTitle: Assessment of Volume-targeted Ventilation in Patients With Neuromuscular Disease, acronym: VT-NMD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Guy's and St Thomas' NHS Foundation Trust, class: OTHER, descriptionModule briefSummary: Assessment of safety and efficacy of volume-targeted ventilation in patients with neuromuscular disease., conditionsModule conditions: Neuromuscular Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Volume-targeted non-invasive ventilation, outcomesModule primaryOutcomes measure: Mean overnight transcutaneous carbon dioxide, secondaryOutcomes measure: Maximum overnight transcutaneous carbon dioxide, secondaryOutcomes measure: Overnight desaturation index, secondaryOutcomes measure: Visual analogue scale of sleep comfort, secondaryOutcomes measure: Health-related quality of life, secondaryOutcomes measure: Adherence to ventilation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Guy's and St. Thomas NHS Foundation Trust, city: London, zip: SE1 7EH, country: United Kingdom, geoPoint lat: 51.50853, lon: -0.12574, locations facility: Guy's & St Thomas' NHS Foundation Trust, city: London, zip: SE1 9RT, country: United Kingdom, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06339554, orgStudyIdInfo id: 4806, briefTitle: Alectinib-induced Endocrine Toxicity, acronym: TOSS-ALK, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-10-12, primaryCompletionDateStruct date: 2023-10-30, completionDateStruct date: 2023-10-30, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: The experimental Cohort A (male ALK+ ANSCLC patients receiving alectinib), the control Cohort B (female ALK+ ANSCLC patients receiving alectinib) and control Cohort C (male NON-ALK ANSCLC patients) were prospectively evaluated for full hormone assessment of androgen deficiency, AT 8 weeks after treatment start and in case of reported suspected symptoms. Patients with major sexual dysfunctions were referred to endocrinologist., conditionsModule conditions: NSCLC Stage IV, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 98, type: ACTUAL, armsInterventionsModule interventions name: Alectinib 150 MG [Alecensa], outcomesModule primaryOutcomes measure: Incidence of endocrine toxicity in overall ALK-positive, primaryOutcomes measure: Incidence of symptomatic hypogonadism in male ANSCLC patients, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione Policlinico Gemelli IRCCS, city: Rome, zip: 00168, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06339541, orgStudyIdInfo id: 029-FPO23, briefTitle: The ACC Preclinical Research Platform for Precision Oncology, acronym: ACC Platform, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-05, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Fondazione del Piemonte per l'Oncologia, class: OTHER, collaborators name: Alleanza Contro il Cancro, descriptionModule briefSummary: The ACC Preclinical Research Platform for Precision Oncology is a retrospective and prospective observational study focused on the implementation and validation of the application of PDCM (Patient Derived Cancer Models) generated from tissues or cells of patients with neoplastic disease, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments., conditionsModule conditions: Solid Tumor, conditions: Hematologic Neoplasms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: OTHER, enrollmentInfo count: 250, type: ESTIMATED, outcomesModule primaryOutcomes measure: number of PDCM (patient derived cancer models), primaryOutcomes measure: number of Whole Exome Sequencing (WES) e RNA-seq performed, secondaryOutcomes measure: number of PDCM shared within the network, eligibilityModule sex: ALL, minimumAge: 14 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo, status: RECRUITING, city: Candiolo, state: Turin, zip: 10060, country: Italy, contacts name: Marco Asioli, BSc, role: CONTACT, phone: +390119933463, email: marco.asioli@ircc.it, contacts name: Enzo Medico, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.95858, lon: 7.59812, hasResults: False
protocolSection identificationModule nctId: NCT06339528, orgStudyIdInfo id: EK-VPl421012021, briefTitle: Potential of Vojta's Reflex Locomotion as a Pre/Induction Method for Uterine Activity: a Pilot Study, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-06-23, primaryCompletionDateStruct date: 2024-01-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Faculty Hospital Kralovske Vinohrady, class: OTHER_GOV, descriptionModule briefSummary: The Vojta's method is neurophysiological rehabilitation method used to support and induce reflex responses of locomotor and vegetative system. It uses involuntary motor reaction of the body during pressure stimulation of so-called trigger zones. Pregnancy is currently considered a contraindication for using Vojta's therapy to potential risks of inducing regular uterine activity and risk of delivery. The aim of the study is to evaluate changes in uterine activity and also explore the possibility of using this method as a new approach for pre/induction of delivery., conditionsModule conditions: Induced Vaginal Delivery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A total of 40 pregnant patients between 40+0 to 41+0 weeks of gestational age were randomly selected for this study. Stimulation of trigger zones according to Vojta's therapy was applied to 20 of them by a team of licensed physiotherapists while a control group received a sham stimulation carried out by physicians. Cardiotocographic (CTG) recordings were conducted right before and immediately after stimulation. CTG recordings were subsequently blindly evaluated by 2 independent obstetricians., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: Stimulation of trigger zones according to Vojta's therapy was applied to 20 of them by a team of licensed physiotherapists while a control group received a sham stimulation carried out by physicians. Cardiotocographic (CTG) recordings were conducted right before and immediately after stimulation. CTG recordings were subsequently blindly evaluated by 2 independent obstetricians. Patients did not know if clinician have skills to stimulate properly according to the Vojta's Reflex Locomotion., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Vojta's Reflex Locomotion, interventions name: Sham stimulation, outcomesModule primaryOutcomes measure: Cardiotocographic (CTG) recordings -, primaryOutcomes measure: subjective perception during stimulation, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty Hospital Kralovske Vinohrady, city: Praha, zip: 11000, country: Czechia, geoPoint lat: 50.08804, lon: 14.42076, hasResults: False
protocolSection identificationModule nctId: NCT06339515, orgStudyIdInfo id: DuzceU-SBF-NYS-02, briefTitle: Teaching School Health Nursing Course With Universal Design Model, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-21, primaryCompletionDateStruct date: 2024-06-06, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Duzce University, class: OTHER, descriptionModule briefSummary: The aim of this study is to design, implement and evaluate the School Health Nursing course in the undergraduate nursing program using the universal design model., conditionsModule conditions: Nursing Education, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Universal Design Model for Learning, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 27, type: ESTIMATED, armsInterventionsModule interventions name: Universal Design Model, outcomesModule primaryOutcomes measure: Critical Thinking Disposition Scale, primaryOutcomes measure: Communication Skills Scale, primaryOutcomes measure: Healthy Living Awareness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nuriye Yıldırım, city: Düzce, state: Duzce, zip: 81620, country: Turkey, contacts name: Atiye Erbaş, PhD, role: CONTACT, phone: +90380 542 11 41, phoneExt: 3533, email: atiyeerbas@duzce.edu.tr, contacts name: PhD, role: CONTACT, contacts name: Nuriye Yıldırım Şişman, PhD, role: SUB_INVESTIGATOR, contacts name: Fahriye Hayırsever, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.83889, lon: 31.16389, hasResults: False